Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
2023 · The Lancet. Gastroenterology & hepatology · 61 citations
https://doi.org/10.1016/s2468-1253(23)00318-7